News from the ECOG-ACRIN Cancer Research Group
January 26, 2022
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, January 2022

Hopes for a return to normalcy in 2022—plus, recent qualitative research identifies surprising barriers to the long-term control of breast cancer
January 26, 2022
Woman talking with doctor

Now Enrolling: EA3202 for Head and Neck Squamous Cell Carcinoma

This phase II/III study is exploring new treatment approaches for patients with recurrent and metastatic head and neck squamous cell carcinoma
January 26, 2022

Come Again? Communicating Clearly About Risk of Recurrence After Early-Stage Breast Cancer

Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence
January 26, 2022

Trial Spotlight: Jarushka Naidoo on the EAQ172 Trial for Steroid-Refractory Pneumonitis

This randomized phase II trial aims to establish which agent, infliximab versus intravenous immunoglobulin, may lead to greatest benefit as pneumonitis treatment for patients receiving PD-1/PD-L1 therapy
January 26, 2022

Institution Spotlight: Georgia NCORP

A Standing Main Member of ECOG-ACRIN since 1993
January 26, 2022
Doctor feels patient's throat

Trial Results: Journal of Clinical Oncology Publishes Final Results of E3311 Phase II Trial for Head and Neck Cancer

A new post-surgery approach for treating HPV-related throat cancer uses less radiation safely and spares the majority of patients from chemotherapy
January 26, 2022
News in Brief

News in Brief, January 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more